Ranbaxy Laboratories

Event Update

BUY

Price	Rs482
Target Price	Rs603
Investment Period	18 months

📥 Angel Broking

Service Truly Personalized

Stock Info				
Sector	Sector Pharmaceutical			
Market Cap (Market Cap (Rs cr) 17,9		17,983	
Beta			0.60	
52 Week Higl	h / Low	5	00/300	
Avg Daily Vol	ume	:	355461	
Face Value (F	Rs)	5		
BSE Sensex			16,154	
Nifty			4,880	
BSE Code		Ę	500359	
NSE Code		RAN	RANBAXY	
Reuters Code		RA	NB.BO	
Bloomberg Code		RI	RBXY IN	
Shareholding	n Patterr) (%)		
Promoters	gratteri	1 (70)	34.8	
Promoters				
MF / Banks / Indian FIs		S	28.3	
FII / NRIs / OCBs			17.2	
Indian Public / Others			19.7	
Abs.	3m	1yr		
Sensex (%)		17.9	162.4	
Ranbaxy (%)	23.6	42.4	2.7	
Sarabjit Kour Nangra				
Tel: 022 - 4040 3800 Ext: 343				
E-mail:sarabjit@angeltrade.com				
Akshat Vya	IS			
Tel: 022 - 404	0 3800 E	xt: 329		
E-mail:akshat.				

Agreements with AstraZeneca

Ranbaxy Pharmaceuticals Inc., a wholly-owned subsidiary of Ranbaxy Laboratories, has entered into several agreements with AstraZeneca. Two of these pertain to its top-selling ulcer treatment drug, Nexium (active pharmaceutical ingredient (API) - *Esomeprazole Magnesium*) while the other agreements cover two other products viz., *Felopdipine ER* capsules and Omeprazole 40mg. The company has indicated that these deals cumulatively provide it a revenue opportunity of US \$1-1.5bn, over 2009 - 2014.

Nexium, which treats stomach ulcers and heartburn, is one of the world's biggest-selling prescription medicines with global sales of US \$5.2bn in 2007 and is the sequel to another drug, *Prilosec*. In the US, the drug had sales of US \$3.8bn in 2007. The agreement settles the patent infringement litigation filed by AstraZeneca for Ranbaxy's ANDA on *Esomeprazole Magnesium*. However, AstraZeneca plans to continue its litigation against Teva Pharmaceutical and Dr Reddy's Laboratories who are also challenging the patent.

Under the agreement, Ranbaxy would be allowed to start exclusive sales of a generic version of the ulcer drug *Nexium* in May 2014 in the US. This means that Ranbaxy will be able to sell its copy without competition for 180 days and enjoy exclusivity on the product. During the six-month exclusivity period we expect the company to gross sales of \$480mn. On a very conservative basis we have built in an NPV of Rs11.8/share for the same.

In another pact signed by the two companies, with respective to Nexium, Ranbaxy will formulate a significant portion of AstraZeneca's US supply of Nexium from May 2010. We have conservatively factored in a 30% supply off-take by AstraZeneca. The agreement also includes provision for supply of raw material to AstraZeneca for producing *Esomeprazole Magnesium* from 2009.

In addition to this, Ranbaxy has also signed an Authorized Generics deal with AstraZeneca for *Felodipine ER* capsules and *Omeprazole* 40mg tablets, respectively. The two products together address a market opportunity of \$400mn in the US. Both the drugs are off-patent and face limited generic competition. We have factored in revenues of \$100mn accruing CY2009 onwards.

Key Financials (Consolidated)				
Y/E December (Rs cr)	CY2006	CY2007	CY2008E	CY2009E
Net Sales	6,013	6,590	7,413	9,163
% chg	17.9	9.6	12.5	23.6
Adj Net Profit	510.9	570.1	676.2	925.0
% chg	95.2	11.6	18.6	36.8
EPS	13.7	15.3	18.2	24.8
EBITDA Margin (%)	12.4	13.6	14.5	15.2
P/E (x)	35.1	31.5	26.5	19.4
P/CEPS (x)	23.9	16.4	18.3	14.2
RoE (%)	20.1	20.1	20.9	25.2
RoCE (%)	16.3	16.0	17.5	19.7
P/BV (x)	6.3	5.4	4.9	4.2
EV/Sales (x)	3.6	3.3	2.9	2.4
EV/EBITDA (x)	24.8	20.8	17.6	14.0

Source: Company, Angel Research; Note: Net Profit have been adjusted for translational gains

1



Pharmaceutical

Outlook and Valuation

This out-court settlement with AstraZeneca marks the fifth such deal done by Ranbaxy to monetize its First-to-File (FTF) opportunities. Last year, the company had entered into four such deals addressing a market opportunity of US \$4bn. These deals have increased the overall visibility of the company's Para-IV pipeline, and hence mitigate the uncertainty with respect to the launch of these products. With this, the company has visibility of FTF product launches through 2008-2010. Based on the current deal, we have factored in upsides conservatively giving a NPV of Rs22.7/share wherein Rs11.8 is on back of the upsides accuring to the company during the exclusivity period, while Rs9.8/share is on the back of contract manufacturing and the rest for distribution of the Authorised Generic products. **We maintain a Buy on the stock, with a revised Target Price of Rs603 (18 months).**



Pharmaceutical

Fund Management & Investment Advisory	(🖀 022 - 4040 3800 / 2835 9600)	
P. Phani Sekhar	Fund Manager - (PMS)	phani.sekhar@angeltrade.com
Research Team	(🖀 022 - 4040 3800 / 2835 9600)	
Hitesh Agrawal	Head - Research, Cement, Media	hitesh.agrawal@angeltrade.com
Sarabjit Kour Nangra	VP-Research, Pharmaceutical	sarabjit@angeltrade.com
Vaishali Jajoo	Automobile	vaishali.jajoo@angeltrade.com
Harit Shah	IT, Telecom	harit.shah@angeltrade.com
Rohit Nagraj	Oil & Gas	rohit.nagraj@angeltrade.com
Pawan Burde	Metals & Mining	pawan.burde@angeltrade.com
Vaibhav Agrawal	Banking	vaibhav.agrawal@angeltrade.com
Girish Solanki	Mid-cap	girish.solanki@angeltrade.com
Shailesh Kanani	Infrastructure, Real Estate	shailesh.kanani@angeltrade.com
Anand Shah	FMCG	anand.shah@angeltrade.com
Sulabh Agrawal	Mid-cap	sulabh.agrawal@angeltrade.com
Puneet Bambha	PMS	puneet.bambha@angeltrade.com
Amit Bagaria	PMS	amit.bagaria@angeltrade.com
Akshat Vyas	Research Associate (Pharmaceutical)	akshat.vyas@angeltrade.com
Neha Idnany	Research Associate - (PMS)	neha.idnany@angeltrade.com
Sandeep Wagle	Chief Technical Analyst	sandeep@angeltrade.com
Ajit Joshi	AVP Technical Advisory Services	ajit.joshi@angeltrade.com
Milan Sanghvi	Sr. Technical Advisor	milan.sanghvi@angeltrade.com
Nitin Kunte	Technical Advisor	nitin.kunte@angeltrade.com
Brijesh Ail	Technical Analyst	brijesh@angeltrade.com
Vaishnavi Jagtap	Technical Analyst	vaishnavi.jagtap@angeltrade.com
Siddharth Bhamre	Fund Manager - Derivatives & Equities	siddarth.bhamre@angeltrade.com
Commodities Research Team		
Amar Singh	Research Head (Commodities)	amar.singh@angeltrade.com
Samson P	Sr. Technical Analyst	samsonp@angeltrade.com
Anuj Gupta	Sr. Technical Analyst	anuj.gupta@angeltrade.com
Girish Patki	Sr. Technical Analyst	girish.patki@angeltrade.com
Commodities Research Team (Fundamentals)		
Badruddin	Sr. Research Analyst (Agri)	badruddin@angeltrade.com
Mandar Pote	Research Analyst (Energy)	mandar.pote@angeltrade.com
Bharathi Shetty	Research Editor	bharathi.shetty@angeltrade.com
Bharat Patil	Production	bharat.patil@angeltrade.com

Research & Investment Advisory: Acme Plaza, 3rd Floor 'A' wing, M.V. Road, Opp Sangam Cinema, Andheri (E), Mumbai - 400 059

Disclaimer

This document is not for public distribution and has been furnished to you solely for your information and must not be reproduced or redistributed to any other person. Persons into whose possession this document may come are required to observe these restrictions.

Opinion expressed is our current opinion as of the date appearing on this material only. While we endeavor to update on a reasonable basis the information discussed in this material, there may be regulatory, compliance, or other reasons that prevent us from doing so. Prospective investors and others are cautioned that any forward-looking statements are not predictions and may be subject to change without notice. Our proprietary trading and investment businesses may make investment decisions that are inconsistent with the recommendations expressed herein.

The information in this document has been printed on the basis of publicly available information, internal data and other reliable sources believed to be true and are for general guidance only. While every effort is made to ensure the accuracy and completeness of information contained, the company takes no guarantee and assumes no liability for any errors or omissions of the information. No one can use the information as the basis for any claim, demand or cause of action.

Recipients of this material should rely on their own investigations and take their own professional advice. Each recipient of this document should make such investigations as it deems necessary to arrive at an independent evaluation of an investment in the securities of companies referred to in this document (including the merits and risks involved), and should consult their own advisors to determine the merits and risks of such an investment. Price and value of the investments referred to in this material may go up or down. Past performance is not a guide for future performance. Certain transactions - futures, options and other derivatives as well as non-investment grade securities - involve substantial risks and are not suitable for all investors. Reports based on technical analysis centers on studying charts of a stock's price movement and trading volume, as opposed to focusing on a company's fundamentals and as such, may not match with a report on a company's fundamentals.

We do not undertake to advise you as to any change of our views expressed in this document. While we would endeavor to update the information herein on a reasonable basis, Angel Broking, its subsidiaries and associated companies, their directors and employees are under no obligation to update or keep the information current. Also there may be regulatory, compliance, or other reasons that may prevent Angel Broking and affiliates from doing so. Prospective investors and others are cautioned that any forward-looking statements are not predictions and may be subject to change without notice.

Angel Broking Limited and affiliates, including the analyst who has issued this report, may, on the date of this report, and from time to time, have long or short positions in, and buy or sell the securities of the companies mentioned herein or engage in any other transaction involving such securities and earn brokerage or compensation or act as advisor or have other potential conflict of interest with respect to company/ies mentioned herein or inconsistent with any recommendation and related information and opinions.

Angel Broking Limited and affiliates may seek to provide or have engaged in providing corporate finance, investment banking or other advisory services in a merger or specific transaction to the

companies referred to in this report, as on the date of this report or in the past.

Ratings (Returns) Buy (> 15%) Accumulate (5 to 15%) Neutral (5 to -5%) Reduce (> -5%) Sell (> -15%)



Ranbaxy Laboratories

Pharmaceutical

Nealth Management :	e-mail:wmshelpdesk@angeltrade.com		Tel : (022) 4035 3100
nvestment Advisory Helpdesk :	e-mail : advisory@angeltrade.com		Tel : (022) 4040 3800
Commodities :	e-mail:commodities@angeltrade.com		Tel: (022) 4035 8600
Feedback :	e-mail:feedback@angeltrade.com		Tel: (022) 2835 5000
Regional Offices:			
Ahmedabad - Harshit Bhavsar	Indore - Pramathu Chowksey	Lucknow - Ejaz Moyi	Pune - Sunita Magnani
Tel: (079) 3007 0749 - 751	Tel: (0731) 3013 360 - 65	Tel: (0522) 6567 826	Tel: (020) 2551 3143 / 2553 0912 - 14
Bengaluru - Dhiraj Pandey	Jaipur - Ranveer Singh	Nagpur - Sanchit Tiwari	Rajkot - Vijay Popat
Tel: (080) 4153 6700 - 03	Jaipur - 302 001 Tel: (0141) 222 3334	Tel: (0712) 3041 500	Tel :(0281) 6451929 / 1910
Chennai - Thiruneer Selvan	Kanpur - Vivek Singh	Nashik - Nilesh Supekar	Surat - Pinky Kothari
Tel: (044) 4226 9000 Fax: 2498 1742	Tel: (0512) 3017 700	Tel: (0253) 6614 235/236	Tel: (0261) 6696 666
Hyderabad - Shiva Shankar	Kolkata - Vijay Kothari	New Delhi - Rohit Pateria	Visakhapatnam - Vamsi Krishna
Tel: (040) 6673 3573 / 74	Tel: (033) 4009 9899	Tel: (011) 4605 6600 / 4151 2555 / 2666	Tel :(0891) 6620 572-75
Private Client Group Offices:			Sub - Broker Marketing:
Mumbai - Prakarsh Gagdani	Rajkot (Race course) - Nishit Maniar		Premier House - Pankaj Mungre
Tel: (022) 4040 3800 Fax: (022) 4040 3899	Mobile : 99989 59982		Tel: (022) 4035 8600
Ahmedabad (C. G. Road) - Arpit Shah Tel: (079) 3007 4049 / 50	Surat - Amit Keshwani Tel : (0261) 6696 666		
Branch Offices:			
Andheri (Lokhandwala) - Muskaan Doultani	Alwar - Ajay Khandelwal	Gurgaon - Pankaj Varma	Porbandar - Ketan Thanki
Tel : (022) 2639 2626 / 3255 0987	Tel: (0144) 2703 561 / 99826 23223	Tel: (0124) 4712 915	Tel : (0286) 221 5310 / 31 / 221 5450
Andheri (W) - Dinesh Nihalani	Ahmedabad (Bapu Nagar) - Milan Kanabar	Himatnagar - Sanjay Patel	Pune - Sameer Amrute/Shraddha Gadekar
Tel: (022) 2635 2345 / 6668 0021	Tel : (079) 3026 0204 / 0205	Tel: (02772) 241 008 / 241 346	Tel : (020) 6620 6591 / 6620 6595
Bandra (W) - Gyan Joshi	Ahmedabad (C. G. Road) - Ritesh Patel	Hyderabad (A S Rao Nagar) - G J Sharma	Pune - (Pentagon) Ishwar Magnani
Tel: (022) 2655 5560 / 70	Tel: (079) 4021 4023	Tel: (040) 4222 2070 - 5	Tel : (020) 6640 8300 / 3052 3220
Bandra (W) - Faruq Wakani	Ahmedabad (Gurukul) - Kaivalya Shah	Hyderabad (Warangal) - Santosh Kumar	Rajkot (202 Race Course) Prashant Ukani
Tel: (022) 6643 2694 - 99	Tel: (079) 6522 5510 / 3012 5492-94	Tel: (0870) 6452 227	Tel : (0281) 2921 568 / 99049 10001
Borivali (W) - Gautam Agarwal	Ahmedabad (Kalupur) - Jicky Thomas	Indore - Alok Rathi	Rajkot (Ardella) Hitesh Rupareliya
Tel:(022) 2895 2600 / 1 / 2	Tel: (079) 3240 7474 / 75	Tel: (0731) 4042 242 / 4044 366 / 4087	Tel : (0281) 2440 266 - 266
Borivali (W) - Tarun Dhami	Ahmedabad (Maninagar) - Ashok Kumar	Jaipur - (Rajapark) Amit Kumar Garg	Rajkot (University Rd.) - Prashant Ukani
Tel: (022) 3092 1969 / 2892 8890	Tel: (079) 3048 0241 / 2 / 5	Tel: (0141) 4000 500, 94143 14448	Tel : (0281) 2577408
Chembur - Rajesh Mehta	Ahmedabad (Ramdevnagar) - Krunal Pandya	Jalgaon - Sandeep Mundra	Rajkot (Bhaktinagar) - Dhaval Dave
Tel:(022) 6703 0210 / 11 /12	Tel : (079) 2692 6401 / 51	Tel: (0257) 3200 906	Tel : (0281) 236 1935 / 329 6881 / 329 8100
Chembur - (Basant) - Atul Dwivedi	Ahmedabad (Sabarmati) - Kaushik Rathi	Jamnagar - Jwalant Shingala	Rajkot (Indira Circle) - Denish Patel
Tel:(022) 3267 9114/ 15/ 16	Tel : (079) 2692 6401 / 51	Tel : (0288) 266 4941 - 44, 3217 790	Tel : (0281) 2585 751, 99258 84848
Fort - Ajit Karandikar	Ahmedabad (Satellite) - Rishi Parghi	Jodhpur - Bharat Purohit	Rajkot (Orbit Plaza) - Hitesh Popat
Tel: (022) 2263 4050-55	Tel: (079) 4000 1000	Tel: (0291) 5100 941 - 948 / 98284 26786	Tel: (0281) 2463 291-94
Ghatkopar (E) - Ashwin Thakkar	Ahmedabad (Shahibaug) - Chirag Raghvani	Junagadh - Nimesh Raichura	Rajkot (Pedak Road) - Murtaja Sadikot
Tel: (022) 6799 3185 - 88 / 2510 1525	Tel: (079) 22861053 / 5 / 6	Tel : (0285) 2622 483 /2622 484	Mobile : 98245 00252
Goregaon (W) - Sanjiv Dhami	Amreli - Nishith Hemani	Kota - Sumit Maheshwari	Rajkot (Star Chambers) - Manish Baradia
Tel: (022) 2878 9401 / 02	Tel: (02792) 228 800/231039-42	Tel : (0744) 5100 470 / 2365 200	Tel : (0281) 2233 230 / 50
Kalbadevi - Viren Ved	Anand - Alay Brahmbhatt	Mehsana - Alipt Doshi	Rajkot (Star Chambers) - Kiran Marthak
Tel: (022) 2243 5599 / 2242 5599	Tel : (02692) 267 041-45	Tel: (02762) 645 291 / 92	Tel : (0281) 2225 401 / 02 / 03
Kandivali (W) - Sachin Ghelani	Ankleshwar - Ankit Mathur	Nadiad - Vipul Patel	Secunderabad - Srinivas
Tel: (022) 2867 3800 / 2867 7032	Tel: (02646) 652 681-85	Tel : (0268) - 2527 230 / 31	Tel : (040) 6690 5192 / 3 / 4
Kandivali (Thakur Village) - Akharam Chaudhary	Baroda - Rashmikant Thakar	Nashik - Nilesh Supekar	Surat (Mahidharpura) - Sameet Kapadia
Tel: (022) 2846 1267 / 1654 / 2056 / 2076	Tel: (0265) 2226 103-04 / 6624 280	Tel: (0253) 6611 201 / 206	Tel: 2402 911 - 915
Malad (E) - Satish Kanwarjani	Baroda (Akota) - Jaydeep Shah	New Delhi (Bhikaji Cama Place) - Sumit zBhuttan	Surat (Parle Point) - Akshay Panwala
Tel: (022) 2880 4440	Tel: (0265) 2355 258 / 6499 286	Tel: (011) 41659 711/12	Tel : (0261) 2257 990 / 909
Malad (W) - Tushar Shah	Baroda (Manjalpur) - Chirag Patel	New Delhi (Lawrence Rd.) - Sanjeev Kumar	Surat (Ring Road) - Piyush Bothra
Tel: (022) 2880 0960 / 68	Mobile : 098252 27403	Tel: (011) 3262 8699 / 8799	Tel : (0261) 6696 666
Mulund (W) - Niraj Anand	Bhavnagar - Apurva Dhami	New Delhi (Pitampura) - Roopal Agarwal	Surendranagar - Prashant Jani
Tel: (022) 2562 2282	Tel: (0278) 2512099 / 755 / 3001717 / 18	Tel: (011) 4700 2380 / 84	Tel : (02752) 325905 / 223305
Powai (E) - Prashant Auti	Bhopal - Sandeep Kothana	New Delhi (Preet Vihar) -Gulshan Khurana	Udaipur - Anurag Jain
Tel: (022) 40262170 / 1 / 2 / 3	Tel :(0755) 3256 663 / 4024 000	Tel: (011) 4242 1105 - 07	Tel - 098870 60723 / 099291 04723
Thane (W) - Rajesh Kumar	Bikaner - Sharad Acharya	Noida - Amit Gupta	Valsad - Vinod Kumbarwadia
Tel: (022) 2539 0786 / 0789 / 0796	Tel :(0151) 2207 148 / 98281 03988	Tel : (0120) 4639900 / 1 / 9	Tel - (02632) 645 344 / 45
Vashi - Punit Chopra	Deesa - Sandip Nayak	Palanpur - Paresh Patel	Vapi - Jalpa Desai
Tel: (022) 2765 4749 / 2251	Mobile: 98795 19881	Tel : (02742) 645 171 / 72	Tel: (0260) 2400 210 / 214 / 236
Vile Parle (W) - Dimple Shah	Gandhinagar - Vivek Thakker	Patan - Shikha Saxena	Varachha - Naimesh Bhavsar
Tel: (022) 2610 2894 / 95	Tel: (079) 4010 1010 - 31	Tel: (02766) 222 306	(0261) 2551633 - 39
Ajmer - Ashwini Kumar	Gondal - Lenin Trivedi	Patel Nagar - Harpreet Singh	Vijayawada - Badrinath Majeti
Mobile: 97845 99807	Tel: (02825) 240 693 / 4	Tel : (011) 45030 600	Tel :(0866) 6636900 / 901/ 902 / 903

Central Support & Registered Office:G-1, Akruti Trade Centre, Road No. 7, MIDC Marol, Andheri (E), Mumbai - 400 093 Tel : 2835 8800 / 3083 7700